Skip to Main Content

Paper Details

Favorable outcomes of NPM1<sup>mut</sup> AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance.
Blood Cancer J
3
2023
Author NameAffiliation
Andy KaempfOHSU Knight Cancer Institute
Jeffrey W TynerOHSU Knight Cancer Institute
  • 1 - 2

Datasets

Release 1.2